peginterferon alfa-2a + ribavirin + nitazoxanide + alfacalcidol

**peginterferon alfa-2a + ribavirin + nitazoxanide + alfacalcidol** is an investigational combination regimen composed of four active pharmaceutical ingredients. Peginterferon alfa-2a is a pegylated recombinant interferon used to stimulate the innate immune response via activation of the JAK/STAT pathway, generally in the treatment of chronic hepatitis C and B[3][4][6][7]. Ribavirin is a nucleoside analogue antiviral that inhibits HCV RNA synthesis and viral replication[3][6]. Nitazoxanide is a thiazolide compound with broad-spectrum antiviral action, believed to enhance host antiviral defenses and modulate cellular innate immune signaling[1][5]. Alfacalcidol is a vitamin D analogue (precursor of calcitriol), which may have immunomodulatory effects and has been studied as an adjuvant to interferon-based therapy for chronic hepatitis C, particularly in older populations, potentially improving sustained virologic response (SVR) rates and reducing relapse, especially in females[2]. This four-drug combination has been explored for chronic hepatitis C virus (HCV) infection, particularly in difficult-to-treat populations and genotypes, aiming to maximize SVR and reduce relapse rates[1][2]. Peginterferon alfa-2a and ribavirin have a long history as standard HCV therapy; nitazoxanide and alfacalcidol are experimental additions to enhance efficacy.